REG - Futura Medical PLC - Liberum Appointed as Nominated Adviser & Broker

Futura MedicalAnnouncement

23/05/2019 07:05

RNS Number : 9076Z
Futura Medical PLC
23 May 2019
 


Futura Medical
 
Appointment of Liberum as Nominated Adviser and Broker
 
23 May 2019
 
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces the appointment, with immediate effect, of Liberum Capital Limited ("Liberum") as its Nominated Adviser and sole Broker.
 
ENDS
 
For further information please contact:
 
Futura Medical plc 

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

 
Nominated Adviser and Broker:

Liberum

Bidhi Bhoma
Euan Brown
Kane Collings

Tel: +44 (0) 20 3100 2000
 
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
 
Notes to editors
 
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
 
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPQLLFLKEFFBBK